SCHEMBL20743045

SCHEMBL20743045

O=C(CCC(F)(F)F)N1CC(c2ccc(F)cn2)C1

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.41
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NAMPT P43490 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20744374 0.88
SCHEMBL20743043 0.86 EPHX2 (0.45) USP30
SCHEMBL20743072 0.80 RAB9A (0.41) MEN1KMT2A
SCHEMBL20743132 0.79 MEN1 (0.39) MEN1KMT2A
SCHEMBL20743069 0.77 KDM1A (0.40) MEN1KMT2ANAMPT
SCHEMBL18711660 0.76 SPR (0.44) USP30NAMPT
SCHEMBL18702160 0.76 SPR (0.42) NAMPT
SCHEMBL20743063 0.75 PSEN1 (0.43) MEN1KMT2A
SCHEMBL20743055 0.75 MAP3K12 (0.44) USP30MEN1KMT2A
SCHEMBL20743136 0.75 PROKR1 (0.40) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11253499-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-02-22 US claimed
EP-3668854-B1 NOVEL COMPOUNDS GLAXOSMITHKLINE IP DEV LTD (GB) 2022-01-12 EP claimed
EP-3668854-A1 NOVEL COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-06-24 EP claimed
US-20200170997-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-06-04 US claimed
CN-111225909-A Novel compounds 葛兰素史密斯克莱知识产权发展有限公司 2020-06-02 CN claimed
WO-2019034702-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-02-21 WO claimed
US-11253499-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-02-22 US disclosed
US-11253499-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-02-22 US disclosed
EP-3668854-B1 NOVEL COMPOUNDS GLAXOSMITHKLINE IP DEV LTD (GB) 2022-01-12 EP disclosed
EP-3668854-A1 NOVEL COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-06-24 EP disclosed
US-20200170997-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-06-04 US disclosed
US-20200170997-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-06-04 US disclosed
CN-111225909-A Novel compounds 葛兰素史密斯克莱知识产权发展有限公司 2020-06-02 CN disclosed
WO-2019034702-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11253499-B2 Compounds SDHA, SDHB, FDPS USP30 4607/4885MEN1 604/4885KMT2A 3837/4885
US-20200170997-A1 NOVEL COMPOUNDS FNTB, SDHA, FDPS USP30 4371/4885MEN1 2095/4885KMT2A 4473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.